| Cloud Solutions for Bio·Pharmaceutical: Enhancing Security, Reducing Costs, and Enabling Growth
JNPMEDI (CEO KwunHo Jeong), a leader in the digital transformation of the bio-pharmaceutical industry, announced on the 14th that it has been selected as an AWS Certified Managed Service Provider (MSP). AWS MSP is an official certification program that helps companies operate their cloud environments more securely and efficiently. With this certification, JNPMEDI will offer cloud solutions tailored to the bio-pharmaceutical industries.
AWS MSP plays a crucial role in the bio-pharmaceutical industries, where data security and regulatory compliance are top priorities. Companies that must adhere to various regulations, such as privacy protection laws, GMP, and GCP, can use AWS's high security standards to safely manage their data. Moreover, by leveraging cloud environments where companies only pay for what they use, JNPMEDI helps reduce initial infrastructure setup costs and enables more efficient research and clinical trials.
With this AWS MSP certification, JNPMEDI plans to assist bio-pharmaceutical companies in conducting research and clinical trials within an optimized cloud environment. This includes ensuring cloud operations comply with security and regulatory requirements, reducing IT burdens through cost optimization, and designing cloud infrastructure that considers scalability and flexibility for research and clinical trials.
As AI and data-driven technologies become increasingly important in the bio-pharmaceutical industries, JNPMEDI is committed to building secure and scalable cloud infrastructures that help companies effectively leverage AI technologies.
JNPMEDI will also showcase its role as an AWS MSP and introduce cloud-based innovative solutions at KIMES 2025 (International Medical Equipment & Hospital Facilities Exhibition), which will take place from March 20th to March 23rd. Attendees will have the opportunity to explore AWS-based clinical data management and medical device operation solutions, as well as security and cost optimization measures in cloud environments.
MinJung Kim, Product Portfolio Manager at JNPMEDI, stated, “As an AWS MSP, we will actively support bio-pharmaceutical companies to conduct their research and clinical trials in a more secure cloud environment. We look forward to sharing more detailed cloud innovation strategies at KIMES 2025, and we appreciate your interest.”
| Cloud Solutions for Bio·Pharmaceutical: Enhancing Security, Reducing Costs, and Enabling Growth
JNPMEDI (CEO KwunHo Jeong), a leader in the digital transformation of the bio-pharmaceutical industry, announced on the 14th that it has been selected as an AWS Certified Managed Service Provider (MSP). AWS MSP is an official certification program that helps companies operate their cloud environments more securely and efficiently. With this certification, JNPMEDI will offer cloud solutions tailored to the bio-pharmaceutical industries.
AWS MSP plays a crucial role in the bio-pharmaceutical industries, where data security and regulatory compliance are top priorities. Companies that must adhere to various regulations, such as privacy protection laws, GMP, and GCP, can use AWS's high security standards to safely manage their data. Moreover, by leveraging cloud environments where companies only pay for what they use, JNPMEDI helps reduce initial infrastructure setup costs and enables more efficient research and clinical trials.
With this AWS MSP certification, JNPMEDI plans to assist bio-pharmaceutical companies in conducting research and clinical trials within an optimized cloud environment. This includes ensuring cloud operations comply with security and regulatory requirements, reducing IT burdens through cost optimization, and designing cloud infrastructure that considers scalability and flexibility for research and clinical trials.
As AI and data-driven technologies become increasingly important in the bio-pharmaceutical industries, JNPMEDI is committed to building secure and scalable cloud infrastructures that help companies effectively leverage AI technologies.
JNPMEDI will also showcase its role as an AWS MSP and introduce cloud-based innovative solutions at KIMES 2025 (International Medical Equipment & Hospital Facilities Exhibition), which will take place from March 20th to March 23rd. Attendees will have the opportunity to explore AWS-based clinical data management and medical device operation solutions, as well as security and cost optimization measures in cloud environments.
MinJung Kim, Product Portfolio Manager at JNPMEDI, stated, “As an AWS MSP, we will actively support bio-pharmaceutical companies to conduct their research and clinical trials in a more secure cloud environment. We look forward to sharing more detailed cloud innovation strategies at KIMES 2025, and we appreciate your interest.”